공시 • Apr 07
hVIVO plc to Report Fiscal Year 2025 Final Results on Apr 15, 2026 hVIVO plc announced that they will report fiscal year 2025 final results at 8:00 AM, GMT Standard Time on Apr 15, 2026 공시 • Nov 27
hVIVO plc Announces Positive Results from Phase IIb Trial hVIVO plc congratulates its client Cidara Therapeutics Inc. which has entered into a definitive agreement under which Merck Sharp & Dohme LLC ("MSD"), through a subsidiary, will acquire Cidara for a total transaction value of approximately $9.2 billion. This transaction underscores the value of hVIVO's unique capabilities in accelerating drug development and validates the Company's strategic role in supporting breakthrough therapies. Cidara's lead candidate, CD388 is an investigational, long-acting, strain-agnostic antiviral agent designed to prevent influenza infection in individuals at higher risk of complications and offers protection against both influenza A and B. CD388 is currently in Phase III clinical development and has received Breakthrough Therapy Designation and Fast Track Designation from the U.S. FDA. hVIVO has partnered with Cidara throughout the development of CD388, delivering critical data that enabled its progression from early proof-of-concept to late-stage trials. Completed in 2023, hVIVO conducted a randomized, double-blind influenza human challenge study in healthy volunteers, providing early proof-of-concept data for CD388 ahead of later stage trials. 59 study participants were enrolled into the study and the primary efficacy analysis comparing the total viral load (area under the curve /AUC) showed a reduction in the CD388 treated arm compared to placebo. Similarly, the peak viral loads measured by both qPCR and cell culture were lowered in CD388 treated participants compared to placebo. This achievement demonstrated hVIVO's ability to execute large-scale field studies with speed and precision. The Phase IIb data read-out showed that all the primary and secondary endpoints were met. The Company continues to support Cidara through Phase III development, acting as a major clinical site for the ongoing multi-site trial. In addition, hVIVO has acted as the central Virology Laboratory for both of Cidara's CD388 Phase IIb and Phase III programs. As part of this service provision hVIVO has provided scientific consultancy, assembled sample collection kits, managed global virology sample logistics, and is responsible for multiple virology and immunology assays including the primary endpoint analysis. 공시 • Nov 11
hVIVO plc Presents Positive Data from Multiple Novel Human Challenge Models hVIVO plc announced key insights from its scientific presentations at the 10th European Scientific Working Group on Influenza ("ESWI") Conference in Valencia, and the World Vaccine Congress Europe in Amsterdam, which both took place in October 2025. hVIVO presented positive data from a number of newly developed human challenge models, all demonstrating an acceptable safety and tolerability profile, reinforcing hVIVO's continued capabilities in accelerating the development of novel challenge agents and its readiness to meet customer demand for innovative and effective clinical trial solutions. Human Metapneumovirus ("hMPV") challenge model hVIVO's Senior Study Physician, Dr Alexander Lima, presented the positive findings from the newly developed, and world's only contemporary-strain hMPV human challenge model. The presentation at ESWI, titled, " Disease characteristics and immunological profiles obtained from newly developed hVIVO human challenge model", highlighted the model's strong performance using a recent 2a strain, which compared favourably against hVIVO's established RSV A model, a benchmark for model performance for this particular virus family. The model demonstrated high infection and symptomatic disease attack rates and robust AUC virology by qRT-PCR, and is now ready and available for vaccine and antiviral human challenge trials. SARS-CoV-2 Omicron challenge model Alex Mann, Senior Director Clinical Science presented, " Development of a SARS-CoV- 2 Omicron BA5 human challenge mode l" at ESWI. A key insight from the presentation was the importance of timing of dosing post-inoculation, particularly in the context of post-exposure prophylaxis. This represents the first commercially available Omicron human challenge model. Respiratory Syncytial Virus B (RSV B) challenge model At the World Vaccine Congress Europe, hVIVO's Chief Scientific Officer, Dr Andrew Catchpole showcased the positive results from hVIVO's new RSV B model titled, " High infection rates achieved with the world' first RSV B challenge models key component of the RSV-hMPV-PIV combination vaccine efficacy testing platform. The data confirmed the robustness of the RSV B model, which is now available for vaccine and anti-viral efficacy testing. The development of the RSV B and hMPV models, along with the Company's collecting of PIV (parainfluenza virus) clinical samples, has enabled the Company to create a comprehensive efficacy testing platform enabling the Company to test individual components of the next generation combination vaccines under development. 공시 • Sep 04
hVIVO plc to Report Q2, 2025 Results on Sep 23, 2025 hVIVO plc announced that they will report Q2, 2025 results on Sep 23, 2025 공시 • Sep 01
Hvivo plc Appoints Shaun Chilton to Board of Directors as Non-Executive Chair with Effect from September 1, 2025 hVIVO plc Shaun Chilton has joined the Board of Directors as Non-Executive Chair with immediate effect. Shaun brings substantial sector-relevant experience and expertise to the Board, underpinned by a track record of delivering strong growth in sales and enterprise value. He brings over 30 years of experience leading and managing both private and public businesses. Shaun was previously Chief Executive Officer of Clinigen Group plc, a global pharmaceutical services group operating in more than 100 countries and has considerable board experience within UK public companies. He is currently Non-Executive Chair of Avacta Group plc, Non-Executive Chair of Kintiga Limited, and Independent Supervisory Board Member of Product Life Group. The following additional information is provided with regards to the appointment of Shaun Edward Chilton, aged57, in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies: Current directorships/partnerships: Avacta Group plc; Bellbrook Consulting Limited; Mustang Bidco Limited; Mustang Midco Limited; Mustang Topco Limited. Former directorships/partnerships (within the last five years): C7 Health Limited; Clinigen Clinical Trials Limited; Clinigen Consulting Limited; Clinigen CTS Limited; Clinigen Gap Limited; Clinigen Healthcare Limited; Clinigen Holdings Limited; Clinigen International Holdings Limited; Clinigen Limited; Clinigen Pharma Limited; Definigen Limited; IDIS GA Limited; IDIS Group Holdings Limited; IDIS Group LimitedIDIS Limited; IDIS MA Limited; IDIS Pharma Limited; Iovance Biotherapeutics UK SP Ltd; Keats Healthcare Limited. 
